The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

N/ANot Yet RecruitingNCT07269288

Peking University Aerospace Center Hospital1,500 enrolled

Overview

This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are: What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Acute Ischemic Stroke

Interventions

Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.COMBINATION_PRODUCT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Inclusion Criteria (1) Inclusion Criteria for Acute Ischemic Stroke Patients: 1. Aged between 18 and 85 years. 2. Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)). 3. Acute onset, with symptoms occurring within 72 hours and being the first episode. 4. Voluntary participation with signed informed consent. (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history). * Exclusion Criteria (1) Exclusion Criteria for Healthy Controls: 1. Patients with cerebrovascular diseases occurring within 72 hours. 2. Pregnant or lactating patients. (2) Exclusion Criteria for Acute Ischemic Stroke Patients: 1. Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients. 2. Patients with coagulation disorders or other hematologic diseases. 3. Patients with severe cardiovascular, pulmonary, or hepatic diseases. 4. Renal dysfunction. 5. Cancer patients. 6. Patients with active gastric ulcers or gastric bleeding. 7. Pregnant or lactating patients.

Outcomes

Primary Outcomes

Evaluate the recurrence, death, and bleeding events of stroke in the research subjects

Including recurrent ischemic stroke events; Death events include hemorrhagic death, vascular death, and acute myocardial infarction events; Intracranial or other bleeding events (refer to the International Classification of Bleeding Events ICD-10 code).

Time frame: Follow up will be conducted at 3 months, 6 months, and 12 months after the patient's discharge, and the main outcome events mentioned above will be evaluated.